메뉴 건너뛰기




Volumn 67, Issue 2, 2012, Pages 151-155

Therapeutic drug monitoring of lacosamide;Suivi thérapeutique pharmacologique du lacosamide

Author keywords

Lacosamide; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 2C19; HARKOSERIDE;

EID: 84864834748     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2012012     Document Type: Article
Times cited : (4)

References (35)
  • 1
    • 84872669358 scopus 로고    scopus 로고
    • Résumé des caractéristiques du produit lacosamide
    • Résumé des caractéristiques du produit lacosamide. Éditions du Vidal 2010
    • (2010) Éditions du Vidal
  • 2
    • 77952211058 scopus 로고    scopus 로고
    • Efficacy and safety of lacosamide in painful diabetic neuropathy
    • Ziegler D, Hidvégi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33: 839-41
    • (2010) Diabetes Care , vol.33 , pp. 839-841
    • Ziegler, D.1    Hidvégi, T.2    Gurieva, I.3
  • 4
    • 78650789188 scopus 로고    scopus 로고
    • Intravenous lacosamide for treatment of status epilepticus
    • Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011; 123: 137-41
    • (2011) Acta Neurol Scand , vol.123 , pp. 137-141
    • Kellinghaus, C.1    Berning, S.2    Immisch, I.3
  • 5
    • 59749093137 scopus 로고    scopus 로고
    • Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy
    • Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009; 14: 429-31
    • (2009) Epilepsy Behav , vol.14 , pp. 429-431
    • Kellinghaus, C.1    Berning, S.2    Besselmann, M.3
  • 6
    • 84859322846 scopus 로고    scopus 로고
    • Adjunctive treatment with lacosamide: An option for generalized epilepsy?
    • Arnold S, Beige A. Adjunctive treatment with lacosamide: an option for generalized epilepsy? Epilepsia 2010; 51(suppl 4): 118
    • (2010) Epilepsia , vol.51 , Issue.SUPPL. 4 , pp. 118
    • Arnold, S.1    Beige, A.2
  • 8
    • 77952665352 scopus 로고    scopus 로고
    • Lacosamide as treatment of epileptic seizures -Cost utility results for Sweden
    • Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures -cost utility results for Sweden. Acta Neurol Scand 2010; 121: 406-12
    • (2010) Acta Neurol Scand , vol.121 , pp. 406-412
    • Bolin, K.1    Berggren, F.2    Forsgren, L.3
  • 9
    • 33846234734 scopus 로고    scopus 로고
    • Lacosamide
    • DOI 10.1016/j.nurt.2006.10.002, PII S1933721306001759, New Antiepileptic Drugs: Discovery, Development, and Update
    • Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics 2007; 4: 145-8 (Pubitemid 46107317)
    • (2007) Neurotherapeutics , vol.4 , Issue.1 , pp. 145-148
    • Doty, P.1    Rudd, G.D.2    Stoehr, T.3    Thomas, D.4
  • 10
    • 58149215498 scopus 로고    scopus 로고
    • Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures
    • Beydoun A, D'Souza J, Hebert D, et al. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009; 9: 33-42
    • (2009) Expert Rev Neurother , vol.9 , pp. 33-42
    • Beydoun, A.1    D'souza, J.2    Hebert, D.3
  • 11
    • 40849086321 scopus 로고    scopus 로고
    • Lacosamide: An investigational drug for adjunctive treatment of partial-onset seizures
    • DOI 10.1358/dot.2008.44.1.1178468
    • Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008; 44: 35-40 (Pubitemid 351397411)
    • (2008) Drugs of Today , vol.44 , Issue.1 , pp. 35-40
    • Ben-Menachem, E.1
  • 12
    • 63449105974 scopus 로고    scopus 로고
    • Lacosamide: In partial-onset seizures
    • Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs 2009; 69: 449-59
    • (2009) Drugs , vol.69 , pp. 449-459
    • Cross, S.A.1    Curran, M.P.2
  • 13
    • 77249137280 scopus 로고    scopus 로고
    • Clinical perspectives on lacosamide
    • Halford JJ, Lapointe M. Clinical perspectives on lacosamide. Epilepsy Curr 2009; 9: 1-9
    • (2009) Epilepsy Curr , vol.9 , pp. 1-9
    • Halford, J.J.1    Lapointe, M.2
  • 14
    • 77949469954 scopus 로고    scopus 로고
    • Lacosamide as treatment for partial epilepsy: Mechanisms of action, pharmacology, effects, and safety
    • Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009; 5: 757-66
    • (2009) Ther Clin Risk Manag , vol.5 , pp. 757-766
    • Kellinghaus, C.1
  • 15
    • 77952727105 scopus 로고    scopus 로고
    • Lacosamide: New adjunctive treatment option for partial-onset seizures
    • Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother 2010; 11: 1595-602
    • (2010) Expert Opin Pharmacother , vol.11 , pp. 1595-1602
    • Chung, S.S.1
  • 16
    • 11144232600 scopus 로고    scopus 로고
    • Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927
    • Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927. Epilepsia 2002; 43(Suppl 7): 170
    • (2002) Epilepsia , vol.43 , Issue.SUPPL. 7 , pp. 170
    • Horstmann, R.1    Bonn, R.2    Cawello, W.3
  • 17
    • 33846242456 scopus 로고    scopus 로고
    • Food does not affect the pharmacokinetics of SPM 927
    • Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 2004; 45(Suppl 7): 307
    • (2004) Epilepsia , vol.45 , Issue.SUPPL. 7 , pp. 307
    • Cawello, W.1    Kropeit, D.2    Schiltmeyer, B.3
  • 18
    • 84872665828 scopus 로고    scopus 로고
    • Lacosamide has low potential for drug-drug interaction
    • Thomas D, Scharfenecker U, Nickel B, et al. Lacosamide has low potential for drug-drug interaction. Epilepsia 2009; 50(Suppl 4): 110
    • (2009) Epilepsia , vol.50 , Issue.SUPPL. 4 , pp. 110
    • Thomas, D.1    Scharfenecker, U.2    Nickel, B.3
  • 19
    • 33846193132 scopus 로고    scopus 로고
    • Bioequivalence of short-time infusions compared to oral administration of SPM 927
    • Kropeit D, Schiltmeyer B, Cawello W, et al. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 2004; 45(Suppl 7): 123
    • (2004) Epilepsia , vol.45 , Issue.SUPPL. 7 , pp. 123
    • Kropeit, D.1    Schiltmeyer, B.2    Cawello, W.3
  • 20
    • 39749167069 scopus 로고    scopus 로고
    • Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures
    • DOI 10.1111/j.1528-1167.2007.01317.x
    • Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49: 418-24 (Pubitemid 351294527)
    • (2008) Epilepsia , vol.49 , Issue.3 , pp. 418-424
    • Biton, V.1    Rosenfeld, W.E.2    Whitesides, J.3    Fountain, N.B.4    Vaiciene, N.5    Rudd, G.D.6
  • 21
    • 34447344551 scopus 로고    scopus 로고
    • Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures
    • DOI 10.1111/j.1528-1167.2007.01188.x
    • Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-17 (Pubitemid 47063096)
    • (2007) Epilepsia , vol.48 , Issue.7 , pp. 1308-1317
    • Ben-Menachem, E.1    Biton, V.2    Jatuzis, D.3    Abou-Khalil, B.4    Doty, P.5    Rudd, G.D.6
  • 22
    • 61849088333 scopus 로고    scopus 로고
    • Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial
    • Halász P, Kälviäinen R, Mazurkiewicz-Beldziñska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-53
    • (2009) Epilepsia , vol.50 , pp. 443-453
    • Halász, P.1    Kälviäinen, R.2    Mazurkiewicz-Beldziñska, M.3
  • 23
    • 77953033494 scopus 로고    scopus 로고
    • Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial
    • Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2009; 50: 958-67
    • (2009) Epilepsia , vol.50 , pp. 958-967
    • Chung, S.1    Sperling, M.R.2    Biton, V.3
  • 24
    • 84864837937 scopus 로고    scopus 로고
    • Clinical experience with lacosamide in difficullt to treat, drug resistant patients
    • Meencke HJ, Dehnicke C, Bartels S. Clinical experience with lacosamide in difficullt to treat, drug resistant patients. Epilepsia 2009; 50(suppl 11): 250
    • (2009) Epilepsia , vol.50 , Issue.SUPPL. 11 , pp. 250
    • Meencke, H.J.1    Dehnicke, C.2    Bartels, S.3
  • 25
    • 79954500459 scopus 로고    scopus 로고
    • The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III clinical trials
    • Gil-Nagel A, Biton V, Fountain N, et al. The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III clinical trials. Epilepsia 2009; 50(Suppl 10): 110
    • (2009) Epilepsia , vol.50 , Issue.SUPPL. 10 , pp. 110
    • Gil-Nagel, A.1    Biton, V.2    Fountain, N.3
  • 26
    • 84872673260 scopus 로고    scopus 로고
    • Fluctuations of lacosamide serum concentrations and relation to tolerability -First clinical experience
    • Scaparra M, Sattler A, Brandt N, et al. Fluctuations of lacosamide serum concentrations and relation to tolerability -First clinical experience. Epilepsia 2009; 50(Suppl 6): 48
    • (2009) Epilepsia , vol.50 , Issue.SUPPL. 6 , pp. 48
    • Scaparra, M.1    Sattler, A.2    Brandt, N.3
  • 27
    • 33846244930 scopus 로고    scopus 로고
    • Pharmacokinetics of the new antiepileptic drugs SPM 927 in human subjects with different age and gender
    • Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drugs SPM 927 in human subjects with different age and gender. Epilepsia 2004; 45(Suppl 7): 313
    • (2004) Epilepsia , vol.45 , Issue.SUPPL. 7 , pp. 313
    • Schiltmeyer, B.1    Cawello, W.2    Kropeit, D.3
  • 28
    • 33846243706 scopus 로고    scopus 로고
    • Low drug-interaction potential of lacosamide
    • Kropeit D, Koch B, Schiltmeyer B, et al. Low drug-interaction potential of lacosamide. J Pain 2005; 6(Suppl 1): S34
    • (2005) J Pain , vol.6 , Issue.SUPPL. 1
    • Kropeit, D.1    Koch, B.2    Schiltmeyer, B.3
  • 29
    • 77954907520 scopus 로고    scopus 로고
    • No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers
    • Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010; 50: 459-71
    • (2010) J Clin Pharmacol , vol.50 , pp. 459-471
    • Cawello, W.1    Nickel, B.2    Eggert-Formella, A.3
  • 30
    • 33846258011 scopus 로고    scopus 로고
    • Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures
    • Jatuzis D, Biton V, Ben-Menachem, et al. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia 2005; 46(Suppl 8): 170
    • (2005) Epilepsia , vol.46 , Issue.SUPPL. 8 , pp. 170
    • Jatuzis, D.1    Ben-Menachem, B.V.2
  • 31
    • 11144238504 scopus 로고    scopus 로고
    • SPM 927 does not interact with valproic acid and carbamazepine
    • Horstmann R, Bonn R, Cawello W, et al. SPM 927 does not interact with valproic acid and carbamazepine. Epilepsia 2003; 44(Suppl 9): 97
    • (2003) Epilepsia , vol.44 , Issue.SUPPL. 9 , pp. 97
    • Horstmann, R.1    Bonn, R.2    Cawello, W.3
  • 32
    • 77955173059 scopus 로고    scopus 로고
    • A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy
    • Greenaway C, Ratnaraj N, Sander JW, et al. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther Drug Monit 2010; 32: 448-52
    • (2010) Ther Drug Monit , vol.32 , pp. 448-452
    • Greenaway, C.1    Ratnaraj, N.2    Sander, J.W.3
  • 33
    • 79951659549 scopus 로고    scopus 로고
    • Saliva and serum lacosamide concentrations in patients with epilepsy
    • Greenaway C, Ratnaraj N, Sander JW, et al. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 2011; 52: 258-63
    • (2011) Epilepsia , vol.52 , pp. 258-263
    • Greenaway, C.1    Ratnaraj, N.2    Sander, J.W.3
  • 34
    • 77954896142 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of the newer anti-epilepsy medications
    • Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel) 2010; 3: 1909-35
    • (2010) Pharmaceuticals (Basel) , vol.3 , pp. 1909-1935
    • Krasowski, M.D.1
  • 35
    • 77955741352 scopus 로고    scopus 로고
    • Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique
    • Le Guellec C, Simon N, Hulot JS, et al. Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique. La Lettre du Pharmacologue 2009; 23: 21-5
    • (2009) La Lettre du Pharmacologue , vol.23 , pp. 21-25
    • Le Guellec, C.1    Simon, N.2    Hulot, J.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.